Fosaprepitant + Dexamethasone + 5HT3
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting
Conditions
Chemotherapy-Induced Nausea and Vomiting
Trial Timeline
Jan 1, 2013 → Jun 1, 2015
NCT ID
NCT01736917About Fosaprepitant + Dexamethasone + 5HT3
Fosaprepitant + Dexamethasone + 5HT3 is a phase 2 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT01736917. Target conditions include Chemotherapy-Induced Nausea and Vomiting.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01736917 | Phase 2 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting